PTC Therapeutics Appoints Jessica Chutter, Who Oversaw $80B Raises and $85B Deals
PTC Therapeutics named biotech investment-banking veteran Jessica Chutter to its Board of Directors, drawing on her four decades at Morgan Stanley where she led the biotechnology franchise and oversaw roughly $80 billion in capital raises and $85 billion in strategic transactions. Her appointment is designed to support PTC’s next growth stage.
1. Board Appointment Details
On March 25, PTC Therapeutics announced the addition of Jessica Chutter to its Board of Directors. Chair Michael Schmertzler highlighted her integral role in guiding the company’s next growth phase, collaborating closely with CEO Matthew Klein and the management team.
2. Chutter's Investment Banking Achievements
Chutter retired as Managing Director and Chair of Biotechnology Investment Banking at Morgan Stanley after a 40-year career. During her tenure she built the biotech franchise and participated in approximately $80 billion of capital raisings and $85 billion of strategic transactions.
3. Strategic Implications for PTC
Chutter’s banking pedigree is expected to enhance PTC’s access to financing and M&A capabilities as it advances its rare-disease pipeline. Her experience in large-scale deals could help optimize PTC’s capital structure and accelerate global commercialization efforts.